Systems pathology-taking molecular pathology into a new dimension

Nature Reviews Clinical Oncology

Volumn 6, Issue 8, 2009, Pages 455-464

  Faratian, Dana ^a   Clyde, Robert G ^b   Crawford, John W ^b   Harrison, David J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF ABERTAY DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; TRASTUZUMAB; ANTINEOPLASTIC AGENT; TUMOR MARKER;

BIOLOGICAL MODEL; BREAST CANCER; CANCER CELL; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CELL FUNCTION; CLINICAL TRIAL; DISEASE MARKER; DISEASE MODEL; DNA MICROARRAY; DRUG MECHANISM; DRUG TARGETING; HISTOPATHOLOGY; HUMAN; MATHEMATICAL MODEL; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NONHUMAN; PREDICTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; TREATMENT RESPONSE; ANTIBODY SPECIFICITY; BIOLOGY; BREAST TUMOR; CELL COMPARTMENTALIZATION; CHEMISTRY; DIAGNOSTIC PROCEDURE; FEMALE; GENE REGULATORY NETWORK; GENETICS; IMAGE PROCESSING; INSTRUMENTATION; METABOLISM; METHODOLOGY; PATHOLOGY; PROGNOSIS; TIME; TUMOR GENE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL COMPARTMENTATION; COMPUTATIONAL BIOLOGY; FEMALE; GENE REGULATORY NETWORKS; GENES, NEOPLASM; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; METABOLIC NETWORKS AND PATHWAYS; MODELS, BIOLOGICAL; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM STAGING; ORGAN SPECIFICITY; PATHOLOGY, CLINICAL; PROGNOSIS; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 70350005352     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.102     Document Type: Review

References (70)

1. Henney, A. & superti-Furga, G. A network solution. Nature 455, 730-731 (2008).
2. Belardinelli, L., shryock, J. C. & Fraser, H. inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 92 (Suppl. 4), iv6-iv14 (2006).
3. Noble, D. & Noble, P. J. Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload. Heart 92 (Suppl. 4), iv1-iv5 (2006).
4. Cho, C. r., Labow, M., reinhardt, M., van Oostrum, J. & Peitsch, M. C. The application of systems biology to drug discovery. Curr. Opin. Chem. Biol. 10, 294-302 (2006).
5. FDA Approves New Treatment for Chest Pain, FDA [online], http://www.fda.gov/Newsevents/ Newsroom/PressAnnouncements/2006/ ucm108587.htm (2009).
6. Berns, K. et al. A functional genetic approach identifies the Pi3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12, 395-402 (2007).
7. valabrega, G., Montemurro, F. & Aglietta, M. Trastuzumab: mechanism of action, resistance and future perspectives in Her2-overexpressing breast cancer. Ann. Oncol. 18, 977-984 (2007).
8. Hanahan, D. & weinberg, r. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
9. sobin, L. H. & wittekind, C. H. UICC: TNM Classification of Malignant Tumor
10. elston, C. w. & ellis, i. O. Pathological prognostic factors in breast cancer. i. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19, 403-410 (1991).
11. reis-Filho, J. s. et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology 49, 10-21 (2006).
12. reis-Filho, J. s. & Tutt, A. N. Triple negative tumours: a critical review. Histopathology 52, 108-118 (2008).
13. Gusterson, B. Do 'basal-like' breast cancers really exist? Nat. Rev. Cancer 9, 128-134 (2009).
14. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
15. Tan, D. s. & reis-Filho, J. s. Comparative genomic hybridisation arrays: high-throughput tools to determine targeted therapy in breast cancer. Pathobiology 75, 63-74 (2008).
16. Turner, N. C. & reis-Filho, J. s. Basal-like breast cancer and the BrCA1 phenotype. Oncogene 25, 5846-5853 (2006).
17. Carey, L. A. et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 13, 2329-2334 (2007).
18. rouzier, r. et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 11, 5678-5685 (2005).
19. Faratian, D. & Bartlett, J. Predictive markers in breast cancer-the future. Histopathology 52, 91-98 (2008).
20. wood, L. D. et al. The genomic landscapes of human breast and colorectal cancers. Science 318, 1108-1113 (2007).
21. Bild, A. H. et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353-357 (2006).
22. early Breast Cancer Trialists' Collaborative Group (eBCTCG). effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
23. smith, i. et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in Her2-positive breast cancer: a randomised controlled trial. Lancet 369, 29-36 (2007).
24. Faratian, D. Moodie, s. L., Harrison D. J. & Goryanin, i. Dynamic computational modeling in the search for better breast cancer drug therapy. Pharmacogenomics 8, 1757-1761 (2007).
25. O'reilly, K. e. et al. mTOr inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500-1508 (2006).
26. Kola, i. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-715 (2004).
27. sherr, C. J. Cancer cell cycles. Science 274, 1672-1677 (1996).
28. Kholodenko, B. N. Cell-signalling dynamics in time and space. Nat. Rev. Mol. Cell Biol. 7, 165-176 (2006).
29. Kholodenko, B. N. & Kolch, w. Giving space to cell signaling. Cell 133, 566-567 (2008).
30. Cohen, A. A. et al. Dynamic proteomics of individual cancer cells in response to a drug. Science 322, 1511-1516 (2008).
31. Kitano, H. Biological robustness. Nat. Rev. Genet. 5, 826-837 (2004).
32. Carlson, J. M. & Doyle, J. Highly optimized tolerance: robustness and design in complex systems. Phys. Rev. Lett. 84, 2529-2532 (2000).
33. sauro, H. M. & Bergmann, F. T. standards and ontologies in computational systems biology. Essays Biochem. 45, 211-222 (2008).
34. Hucka, M. et al. The systems biology markup language (sBML): a medium for representation and exchange of biochemical network models. Bioinformatics 19, 524-531 (2003).
35. Fuss, H., Dubitzky, w., Downes, C. s. & Kurth, M. J. Mathematical models of cell cycle regulation. Brief. Bioinform. 6, 163-177 (2005).
36. Hatakeyama, M. et al. A computational model on the modulation of mitogen-activated protein kinase (MAPK) and Akt pathways in heregulininduced erbB signalling. Biochem. J. 373, 451-463 (2003).
37. Hendriks, B. s. et al. Computational modelling of erbB family phosphorylation dynamics in response to transforming growth factor alpha and heregulin indicates spatial compartmentation of phosphatase activity. Syst. Biol. (Stevenage) 153, 22-33 (2006).
38. Kholodenko, B. N., Demin, O. v., Moehren, G. & Hoek, J. B. Quantification of short term signaling by the epidermal growth factor receptor. J. Biol. Chem. 274, 30169-30181 (1999).
39. Markevich, N. i., Hoek, J. B. & Kholodenko, B. N. signaling switches and bistability arising from multisite phosphorylation in protein kinase cascades. J. Cell Biol. 164, 353-359 (2004).
40. shankaran, H., wiley, H. s. & resat, H. Modeling the effects of Her/erbB1-3 coexpression on receptor dimerization and biological response. Biophys. J. 90, 3993-4009 (2006).
41. steuer, r. Computational approaches to the topology, stability and dynamics of metabolic networks. Phytochemistry 68, 2139-2151 (2007).
42. schoeberl, B., eichler-Jonsson, C., Gilles, e. D. & Muller, G. Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized eGF receptors. Nat. Biotechnol. 20, 370-375 (2002).
43. Janes, K. A. et al. A systems model of signaling identifies a molecular basis set for cytokineinduced apoptosis. Science 310, 1646-1653 (2005).
44. Demin, O. & Goryanin, i. Kinetic Modelling in Systems Biology. (Chapman and Hall/CrC, Boca raton, FL, 2008).
45. Berns, K. et al. A functional genetic approach identifies the Pi3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12, 395-402 (2007).
46. Nagata, Y. et al. PTeN activation contributes to tumor inhibition by trastuzumab, and loss of PTeN predicts trastuzumab resistance in patients. Cancer Cell 6, 117-127 (2004).
47. Barabasi, A. L. & Oltvai, Z. N. Network biology: understanding the cell's functional organization. Nat. Rev. Genet. 5, 101-113 (2004).
48. Clyde, r. G., Bown, J. L., Hupp, T. r., Zhelev, N. & Crawford, J. w. The role of modelling in identifying drug targets for diseases of the cell cycle. J. R. Soc. Interface 3, 617-627 (2006).
49. Goldberg, D. Genetic Algorithms in Search, Optimization, and Machine Learning. (Addisonwesley, reading, MA, 1989).
50. Noble, D. systems biology and the heart. Biosystems 83, 75-80 (2006).
51. Brewer, D., Barenco, M., Callard, r., Hubank, M. & stark, J. Fitting ordinary differential equations to short time course data. Philos. Transact. A Math. Phys. Eng. Sci. 366, 519-544 (2008).
52. sorribas, A. & savageau, M. A. A comparison of variant theories of intact biochemical systems. i. enzyme-enzyme interactions and biochemical systems theory. Math. Biosci. 94, 161-193 (1989).
53. Cascante, M. et al. Metabolic control analysis in drug discovery and disease. Nat. Biotechnol. 20, 243-249 (2002).
54. savageau, M. A. & voit, e. O. Power-law approach to modeling biological systems. 1. Theory. J. Ferment. Technol. 60, 221-228 (1982).
55. voit, e. O. Models-of-data and models-of-processes in the post-genomic era. Math. Biosci. 180, 263-274 (2002).
56. Bosl, w. J. systems biology by the rules: hybrid intelligent systems for pathway modeling and discovery. BMC Syst. Biol. 1, 13 (2007).
57. Kirby, J., Heath, P. r., shaw, P. J. & Hamdy, F. C. Gene expression assays. Adv. Clin. Chem. 44, 247-292 (2007).
58. Kennett, J. Y., watson, s. K., saprunoff, H., Heryet, C. & Lam, w. L. Technical demonstration of whole genome array comparative genomic hybridization. J. Vis. Exp. 5, 870 (2008).
59. edwards, r. A. Laser capture microdissection of mammalian tissue. J. Vis. Exp. 309 (2007).
60. Camp, r. L., Chung, G. G. & rimm, D. L. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat. Med. 8, 1323-1327 (2002).
61. Pan, s. et al. Mass spectrometry based targeted protein quantification: methods and applications. J. Proteome Res. 8, 787-797 (2008).
62. Tibes, r. et al. reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol. Cancer Ther. 5, 2512-2521 (2006).
63. Kedrin, D. et al. intravital imaging of metastatic behavior through a mammary imaging window. Nat. Methods 5, 1019-1021 (2008).
64. edward, M. Melanoma cell-derived factors stimulate glycosaminoglycan synthesis by fibroblasts cultured as monolayers and within contracted collagen lattices. Br. J. Dermatol. 144, 465-470 (2001).
65. Dixon, J. M. The scientific value of preoperative studies and how they can be used. Breast Cancer Res. Treat. 87 (Suppl. 1), s19-s26 (2004).
66. Dowsett, M. et al. Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin. Cancer Res. 12, 1024s-1030s (2006).
67. Dowsett, M. et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J. Natl Cancer Inst. 99, 167-170 (2007).
68. Alberts, D. s. et al. intraperitoneal therapy for stage iii ovarian cancer: a therapy whose time has come¡ J. Clin. Oncol. 20, 3944-3946 (2002).
69. Nagtegaal, i. D. et al. radiation induces different changes in expression profiles of normal rectal tissue compared with rectal carcinoma. Virchows Arch. 446, 127-135 (2005).
70. Dolled-Filhart, M. et al. Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res. 66, 5487-5494 (2006).